Brief: GSK To Acquire Nuvalent For $10.6 Billion
BRIEF-GSK To Acquire Nuvalent For $10.6 Billion June 9 (Reuters) - GSK plc GSK.L:
GSK PLC - GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC.
GSK - ANNOUNCES AGREEMENT TO BUY NUVALENT FOR $10.6 BILLION
GSK: ACQUISITION EXPECTED TO BE ACCRETIVE TO SALES AND CORE OPERATING PROFIT IN 2027
GSK - TO BUY NUVALENT SHARES AT $124 PER SHARE IN CASH
GSK - ACQUISITION EXPECTED TO BE ACCRETIVE TO SALES AND CORE OPERATING PROFIT IN 2027, CORE EPS IN 2029
GSK - REAFFIRMS 70P EXPECTED DIVIDEND FOR 2026
GSK - DEAL EXPECTED TO RESULT IN LOW SINGLE-DIGIT CORE EPS DILUTION FY2026-FY2028
GSK: NO CHANGE TO GSK'S 2026 FULL-YEAR GUIDANCE RANGE OF 7-9% CORE OPERATING PROFIT AND CORE EPS GROWTH
GSK: TRANSACTION WILL BE FUNDED PRIMARILY FROM NEW AND EXISTING DEBT FACILITIES PLUS CASH
GSK: WILL ASSUME NUVALENT'S EXISTING REVENUE-SHARING ARRANGEMENTS OF LOW-SINGLE-DIGIT ROYALTIES PAYABLE TO ROYALTY PHARMA AND DEERFIELD
GSK - ANNOUNCES AGREEMENT TO BUY NUVALENT FOR $10.6 BILLION
Source text: ID:nRSI5506Ha
Further company coverage: GSK.L